AT-533

• UNSPSC Description:

  AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs)[1][2][3].

• Target Antigen:

  Akt; ERK; FAK; HIF/HIF Prolyl-Hydroxylase; HSP; HSV; NF-κB; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage;MAPK/ERK Pathway;Metabolic Enzyme/Protease;NF-κB;PI3K/Akt/mTOR;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/at-533.html

• Solubility:

  DMSO : 33.33 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CC1=NN(C2=CC(N[C@@H]3CC[C@H](CC3)O)=C(C=C2)C(N)=O)C(CC(C)(C4)C)=C1C4=O

• Molecular Weight:

  410.51

• References & Citations:

  [1]Zhang PC, et al. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo. Biochem Pharmacol. 2020 Feb;172:113771. |[2]Li F, et al. AT-533, a Hsp90 inhibitor, attenuates HSV-1-induced inflammation. Biochem Pharmacol. 2019 Aug;166:82-92. |[3]Wu Y, et al. Subacute toxicological evaluation of AT-533 and AT-533 gel in Sprague-Dawley rats. Exp Ther Med. 2021 Jun;21(6):632.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  908112-37-8